Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01852214 · ClinicalTrials.gov registry record · NA
Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT01852214 is a NA study that has completed, run by University of Florida. The registered enrollment target is 50 participants.
The verdict
NCT01852214, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
Patients with diabetes mellitus (DM) have an increased risk of adverse atherothrombotic events. This may be in part attributed to the fact that these patients have reduced response to oral antiplatelet medications, in particular the P2Y12 receptor inhibitor clopidogrel, used for secondary prevention of ischemic events. Prasugrel and ticagrelor are recently approved P2Y12 receptor inhibitors which, compared with clopidogrel, have more potent antiplatelet effects. Head-to-head comparisons between the two drugs are lacking.
Interventions
- DRUG Prasugrel
- DRUG Ticagrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01852214
The ClinicalTrials.gov registry entry for NCT01852214 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prasugrel is the first listed.
NCT01852214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01852214 about?
NCT01852214 is a clinical study titled "Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes". Patients with diabetes mellitus (DM) have an increased risk of adverse atherothrombotic events. This may be in part attributed to the fact that these patients have reduced response to oral antiplatelet medications, in particular the P2Y12 receptor inhibitor clopidogrel, used for secondary prevention...
What is the current status of trial NCT01852214?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2013-02. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01852214?
The interventions under investigation include: Prasugrel (DRUG), Ticagrelor (DRUG).
Who is sponsoring clinical trial NCT01852214?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.